VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) | VYVGART (efgartigimod alfa-fcab) VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) | VYVGART (efgartigimod alfa-fcab)
Prescription medicines for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG)
MENU

Questions? Call 1-833-VYVGART (1-833-898-4278)

Prescription medicines for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG)
STAY UP TO DATE

Questions? Call 1-833-VYVGART (1-833-898-4278)

Prescription medicines for adults with anti-AChR antibody positive gMG

AChR=acetylcholine receptor.

Two proven treatments, for MY gMG

VYVGART for IV infusion:

Improved daily abilities and reduced muscle weakness

Learn more about the
VYVGART for IV infusion study

VYVGART Hytrulo for subcutaneous injection:

Had a similar effect on harmful AChR antibodies that cause gMG symptoms compared to VYVGART for IV infusion

Learn more about the
VYVGART Hytrulo study

Make the days count with VYVGART

Results from a clinical study of VYVGART for IV infusion

Significantly improved daily abilities*

68% of patients (44 of 65) had significantly improved daily abilities on VYVGART for IV infusion + current oral gMG treatment vs. 30% of patients (19 of 64) on placebo + current oral gMG treatment.

Results were measured by the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale in treatment cycle 1 (by week 8).

With VYVGART, my daily abilities have improved, and my symptoms have been better managed.”

Doug

Started on VYVGART for IV infusion in 2022

Doug is a paid spokesperson.

He was not part of the clinical studies.

That’s more than 2x as many
patients vs. placebo

*Defined as a decrease of 2 or more points on the MG-ADL scale, which measures the severity of 8 common symptoms of gMG, maintained for at least 4 weeks. A lower MG-ADL score means less severe symptoms.

Results from a clinical study of VYVGART for IV infusion

Significantly reduced muscle weakness†

63% of patients (41 of 65) had significantly reduced muscle weakness on VYVGART for IV infusion + current oral gMG treatment vs. 14% of patients (9 of 64) on placebo + current oral gMG treatment.

Results were measured by the Quantitative Myasthenia Gravis (QMG) scale in treatment cycle 1 (by week 8).

With VYVGART, I’m able to play with my kids and have fun with my family.”

Niki

Started on VYVGART for IV infusion in 2022

Niki is a paid spokesperson.

She was not part of the clinical studies.

That’s more than 4x as many
patients vs. placebo

†Defined as a decrease of 3 or more points on the QMG scale, which assesses muscle weakness based on 13 items, maintained for at least 4 weeks. A lower QMG score means less muscle weakness.

Average change in symptoms during treatment cycle 1

Patients had an average improvement of 4.6 points on their MG-ADL score at 4 weeks while on VYVGART for IV infusion + current oral gMG treatment vs. 1.8-point improvement on placebo + current oral gMG treatment.

smile-chart.svg

Swipe to see full graph

a Patients did not come in for an evaluation at week 9.

 

Average change in MG-ADL score

Week

VYVGART for IV infusion
+ current oral gMG treatment

Placebo
+ current oral gMG treatment

0

0

0

1

-2.2

-1.1

2

-3.7

-1.4

3

-4.1

-1.4

4

-4.6

-1.8

5

-4.4

-1.8

6

-4.1

-1.4

7

-3.4

-1.7

8

-2.2

-1.7

9a

-

-

10

-1.6

-1.0

a Patients did not come in for an evaluation at week 9.

Additional data from the VYVGART for IV infusion study

The following data points were not the main goals of the study and do not carry the same weight as the main goals of the study. No reliable conclusions can be drawn about the effectiveness or safety of VYVGART for IV infusion based on these data points.

Percentage of patients observed to have minimal to no symptoms during at least 1 visit in treatment cycle 1

Minimal to no symptoms means having an MG-ADL score of 0 or 1

VYVGART for
IV infusion

+ current oral
gMG treatment

Placebo

+ current oral
gMG treatment

Learn more about the #1 prescribed branded biologic treatments for MY gMG‡

VYVGART safety

Learn about safety and side effects for VYVGART for IV infusion and VYVGART Hytrulo for subcutaneous injection.

See the safety profile

VYVGART dosing

Breaks between VYVGART treatment cycles are personalized to you. Find out how to work with your doctor to make the most of your treatment plan.

Learn about personalized breaks

VYVGART Videos

Learn about VYVGART, watch patient stories, and hear from gMG experts. You’ll get access to helpful information about a patient support program, symptom tracking, and much more.

Explore the videos

‡VYVGART for IV infusion and VYVGART Hytrulo for subcutaneous injection are the combined #1 prescribed FDA-approved biologic treatments for adults with anti-AChR antibody positive gMG. Based on IQVIA LAAD from January 2023 to December 2024. Data is based on validated open claims of VYVGART for IV infusion, VYVGART Hytrulo for subcutaneous injection, oral products, and other biologics that have been approved by the FDA for the treatment of adults with generalized myasthenia gravis. Patients who had more than one medical claim in this dataset were counted only once, based on a pre-defined hierarchy.

Still have questions? Call 1-833-VYVGART (1-833-898-4278) to speak with an educator about gMG, how VYVGART works in the body, study data, cost and coverage, and more.

Do not take VYVGART if you are allergic to efgartigimod alfa or any of the ingredients in VYVGART. Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART or VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART or VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • have recently received or are scheduled to receive any vaccinations.
  • have any history of allergic reactions.
  • have kidney (renal) problems.
  • are pregnant or plan to become pregnant. It is not known whether VYVGART or VYVGART HYTRULO will harm your unborn baby.
    • Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART or VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
  • are breastfeeding or plan to breastfeed. It is not known if VYVGART or VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART or VYVGART HYTRULO can cause side effects which can be serious, including:

  • Infection. VYVGART or VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART or VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
    • fever
    • chills
    • frequent and painful urination
    • cough
    • pain and blockage of nasal passages
    • wheezing
    • shortness of breath
    • sore throat
    • excess phlegm
    • nasal discharge

  • Allergic reactions (hypersensitivity reactions). VYVGART or VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction with VYVGART or VYVGART HYTRULO:

    • rash
    • swelling of the face, lips, throat, or tongue
    • shortness of breath
    • trouble breathing
    • low blood pressure
    • fainting

    An additional symptom of an allergic reaction with VYVGART HYTRULO can include hives.

  • Infusion or injection-related reactions. VYVGART can cause infusion-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
    • high blood pressure
    • chills
    • shivering
    • chest, stomach, or back pain

The most common side effects of VYVGART or VYVGART HYTRULO include respiratory tract infection, headache, and urinary tract infection. An additional common side effect with VYVGART HYTRULO includes injection site reactions.

These are not all the possible side effects of VYVGART or VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines used to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

It is not known if VYVGART or VYVGART HYTRULO is safe and effective in children.

Please see full Prescribing and Patient Information for VYVGART HYTRULO for subcutaneous injection and full Prescribing Information for VYVGART for IV infusion.

Dosage forms and strengths:

VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial. VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.

Do not take VYVGART if you are allergic to efgartigimod alfa or any of the ingredients in VYVGART. Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART or VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART or VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • have recently received or are scheduled to receive any vaccinations.
  • have any history of allergic reactions.
  • have kidney (renal) problems.
  • are pregnant or plan to become pregnant. It is not known whether VYVGART or VYVGART HYTRULO will harm your unborn baby.
    • Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART or VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
  • are breastfeeding or plan to breastfeed. It is not known if VYVGART or VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART or VYVGART HYTRULO can cause side effects which can be serious, including:

  • Infection. VYVGART or VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART or VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
    • fever
    • chills
    • frequent and painful urination
    • cough
    • pain and blockage of nasal passages
    • wheezing
    • shortness of breath
    • sore throat
    • excess phlegm
    • nasal discharge

  • Allergic reactions (hypersensitivity reactions). VYVGART or VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction with VYVGART or VYVGART HYTRULO:

    • rash
    • swelling of the face, lips, throat, or tongue
    • shortness of breath
    • trouble breathing
    • low blood pressure
    • fainting

    An additional symptom of an allergic reaction with VYVGART HYTRULO can include hives.

  • Infusion or injection-related reactions. VYVGART can cause infusion-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
    • high blood pressure
    • chills
    • shivering
    • chest, stomach, or back pain

The most common side effects of VYVGART or VYVGART HYTRULO include respiratory tract infection, headache, and urinary tract infection. An additional common side effect with VYVGART HYTRULO includes injection site reactions.

These are not all the possible side effects of VYVGART or VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines used to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

It is not known if VYVGART or VYVGART HYTRULO is safe and effective in children.

Please see full Prescribing and Patient Information for VYVGART HYTRULO for subcutaneous injection and full Prescribing Information for VYVGART for IV infusion.

Dosage forms and strengths:

VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial. VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.

Questions? Call 1-833-VYVGART
(1-833-898-4278)

This site is intended for patients and caregivers.

Disclaimer | Privacy Policy | Contact Us |

Patient and Prescribing Information
VYVGART Hytrulo Patient Information VYVGART Hytrulo Prescribing Information VYVGART Hytrulo Prefilled Syringe Instructions for Use VYVGART for IV Infusion Prescribing Information

VYVGART and VYVGART Hytrulo are registered trademarks of argenx.

For U.S. audiences only.

©2025 argenx 

US-VYV-23-00228 V9 09/2025

argenx